Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Health Group Corporation (also referenced as Propanc Biopharma, Inc.) on February 3, 2017, covering events occurring on January 27, 2017. The filing details the entry into a material definitive agreement involving the issuance of debt securities.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements such as revenue, profit, cash flow, or operating margins. The primary financial activity reported is a debt financing transaction:
- Instrument: Two 8% convertible redeemable junior subordinated promissory notes.
- Principal Amount: $230,000 per note (Total $460,000).
- Counterparty: Eagle Equities, LLC.
- Funding Structure:
- First Note: Funded with cash.
- Eagle Back-End Note: Initially funded via an offsetting promissory note (Note Receivable) issued by Eagle Equities to the Company, due September 27, 2017. Cash funding is required prior to conversion.
- Maturity: One year from issuance (January 27, 2018).
- Conversion Terms: Convertible into common stock at 60% of the lowest closing bid price for the ten trading days prior to conversion.
- Default Interest: 24% per annum or the highest rate permitted by law upon an event of default.
Material Changes Versus Prior Period
This filing represents a discrete event rather than a periodic financial report. Consequently, there are no comparative revenue or earnings changes versus a prior period. The material change is the creation of a new direct financial obligation totaling $460,000 in principal, subject to specific funding and cancellation conditions.
Guidance, Risks, and Contingencies
The filing outlines several risks and contingencies associated with the new debt instruments:
- Cancellation Risk: The Eagle Back-End Note and the associated Note Receivable will be immediately cancelled if the Company's shares do not maintain a minimum trading price and aggregate dollar trading volume during the five days prior to funding.
- Interdependency: If the First Note is redeemed within the first six months of issuance, the Eagle Back-End Note is deemed cancelled.
- Prepayment Penalties: The First Note may be prepaid within 180 days subject to penalties; the Eagle Back-End Note may not be prepaid.
- Default Provisions: Events of default trigger immediate payment of principal and accrued interest, increased interest rates (24%), and potential penalty/liquidated damage provisions.
- Regulatory Exemption: The securities were issued under Section 4(a)(2) of the Securities Act of 1933, relying on the acquirer's representation that the securities were acquired for their own account with no intent to distribute.
Investor Verification Checklist
- Verify the current trading price and volume of Propanc Health Group Corporation common stock to assess the risk of the Eagle Back-End Note cancellation.
- Confirm the status of the "Note Receivable" from Eagle Equities and whether cash funding for the Back-End Note has occurred.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Promissory Notes (Exhibits 4.1 and 4.2) for specific definitions of "events of default" and prepayment penalty calculations.
- Assess the dilution impact of the conversion price (60% of the lowest closing bid) on existing shareholders.
- Check for any subsequent filings regarding the repayment or conversion of these notes.